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Abstract We report the primary characterization of a new
gene KCNRG mapped at chromosome band 13q14.3. This
gene includes three exons and has two alternatively spliced iso-
forms that are expressed in normal tissues and in some tumor
cell lines. Protein KCNRG has high homology to tetrameriza-
tion domain of voltage-gated K+ channels. Using the patch-
clamp technique we determined that KCNRG suppresses K+
channel activity in human prostate cell line LNCaP. It is known
that selective blockers of K+ channels suppress lymphocyte and
LNCaP cell line proliferation. We suggest that KCNRG is a
candidate for a B-cell chronic lymphocytic leukemia and pros-
tate cancer tumor suppressor gene.
- 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Deletions in chromosomal band 13q14.3 have been previ-
ously associated with several di¡erent tumor types, including
B-cell chronic lymphocytic leukemia (BCLL) [1] and prostate
cancer [2], indicating importance of this region for suppres-
sion of a tumor development. The well-known tumor suppres-
sor gene RB1 located at chromosome 13q has been excluded
as potential candidate for these diseases [3], implying the ex-
istence of one or more tumor-suppressor genes in this region.
Previously it was demonstrated that the region bordered by
STS markers D13S1168 and D13S25 is frequently deleted in
tumor cells form patients with BCLL [4,5]. The indicated area
is immersed in a wider region that is deleted in prostate cancer
samples [6,7]. Four candidate genes belonging to this region,
namely DLEU1 and DLEU2 [4], RFP2 [8], C13ORF1 [9] were
cloned. All candidates have been extensively checked for mu-
tations by SSCP analysis and have failed to detect small mu-
tations in any of these genes ([4] and our unpublished data on
C13ORF1, and RFP2). These data suggest the existence of a
di¡erent tumor suppressor gene, located in the area of inter-
est.
In several cell types, enhanced Kþ channel gene expression
or increased Kþ channel activity has been found to be asso-
ciated with cell division [10]. Important role of voltage-gated
Kþ channels in mitogenic growth control has been shown for
human lymphocytes [11]. A high expression of EAG channels
inhibited by physiological [Ca2þ]i has been demonstrated in
several human melanoma [12] and somatic cancer cell lines
[13]. In human prostate cancer, LNCaP cells, the Kþ channels
controlling proliferation are also inhibited by [Ca2þ]i [14]. It
has been suggested that TEA [15^19] and verapamil [20^23]
inhibit the cancer cell proliferation by suppressing Kþ channel
activity. We have previously demonstrated that in the andro-
gen-sensitive prostate cancer cell line LNCaP the rate of the
mitoses is decreased when voltage-activated Kþ channels are
blocked implying that Kþ channels are involved in prostate
cell proliferation [24,25].
Here we report genomic organization and tissue distribu-
tion of the new human gene KCNRG located between
D13S1168 and D13S25. KCNRG encodes a soluble protein
that shows strong homology to the cytoplasmic tetrameriza-
tion domain (T1) of voltage-gated Kþ channels. We suggest
that such protein might interfere with the normal assembly of
the Kþ channel protein by binding to their tetramerization
domain causing the suppression of the Kþ channels. We
also examine the suppressor e¡ect of KCNRG expression on
the whole-cell potassium currents in human prostate cell line
LNCaP by the patch-clamp method. The results of our re-
search suggest that KCNRG is a strong candidate for a
long-searched BCLL and prostate cancer tumor suppressor
gene in human 13q14.3.
2. Materials and methods
2.1. Molecular cloning of a new gene KCNRG
To isolate a new gene KCNRG we have performed a BLASTN
search of the expressed sequence tag (EST) database of GenBank
with genomic sequence accession number AF440619 as a bait. We
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retrieved two expressed human sequences with the accession numbers
BI770863 and BG537776. Corresponding cloned cDNAs IMAGE:
5207702 and IMAGE: 4690662 were obtained from ATCC USA.
The plasmid cDNAs were isolated and completely sequenced using
the following primers: NGf: 5P-GGTAGCCTCTAGTTTGAAGTG-
3P ; NGr: 5P-GAGGCAGTGGAAGTAAGGTC-3P ; NGf871: 5P-
GAAATGAAGTTGTCTATCCTC-3P ; NGr871: 5P-GAGGATAGA-
CAACTTCATTTC-3P ; NGr110: 5P-GGAAAGATGTATTGAAGG-
TAG-3P and standard M13-rev and M13-forv sequencing primers.
2.2. RT-PCR analysis
A number of human poly(A) RNAs samples (Clontech, Palo Alto,
CA, USA) were reverse transcribed to generate ¢rst-strand cDNAs
with Advantage RT-for-PCR kit (Clontech, USA). PCR was carried
out with these ¢rst-strand cDNAs, corresponding to 5 ng poly(A)
RNA, with GenePakTM PCR Universal 100 (IsoGene, Russia) using
the following primer pair NGf and NGr110. PCR was performed for
35 and 39 cycles at 94‡C for 1 min, 58‡C for 1 min and 72‡C for 1 min.
The ampli¢ed fragments were sequenced on both strands. As a con-
trol, GAPDH was ampli¢ed using speci¢c primers (Clontech, USA).
2.3. Plasmid construction
KCNRG cDNA encompassing the entire coding region was synthe-
sized by PCR ampli¢cation of cDNA insert from clone IMAGE:
4690662 using two gene-speci¢c primers. A sense primer, containing
a XhoI site at its 5P-end (NgreF: 5P-TATCTCGAGATGAGTAGT-
CAGGAACTGGT-3P) and an antisense primer, containing a BamHI
site at its 5P-end (NgreR: 5P-TATGGATCCATACCTGTAATCC-
CAGCTA-3P) were used. 500 ng of the pEGFP-N1 vector (Clontech,
USA) and PCR product were digested by XhoI and BamHI. The
digested vector and the PCR products were gel puri¢ed, ligated to-
gether and cloned. The cDNA insert was sequenced to verify its iden-
tity and absence of mutation.
2.4. Electrophysiological studies
LNCaP cells from the ATCC were grown and prepared for electro-
physiological experiments as described previously [14,25]. The whole-
cell modes of the patch-clamp technique were used. This technique
has been described in detail in previous publications [14,25].
The extracellular solution contained (in mM): 140 NaCl, 5 KCl,
2 CaCl2, 2 MgCl2, 0.3 Na2HPO4, 0.4 KH2PO4, 4 NaHCO3, 5 glucose
and 10 HEPES (N-2-hydroxyethylpiperazine-NP-2-ethano-sulfonic
acid). The osmolarity of the external salt solution was adjusted to
310^315 mosmol l31 with sucrose, and the pH adjusted to 7.3O 0.01
using NaOH. The internal solution contained (in mM): 140 KGlu,
1 MgCl2, 0.5 CaCl2, 8 EGTA (ethylene glycol bis L-aminoethyl ether-
N,N,NP,NP-tetraacetic acid), and 5 HEPES (pH 7.2O 0.01 with KOH),
osmolarity 300 mosmol l31. We have previously shown that the Kþ
channel open probability decreased as internal free Ca2þ was aug-
mented from 0.01 WM in the standard internal solution to 0.2^1 WM
[14]. Therefore, in all the experiments in this study, the free Ca2þ
concentration for the solutions applied from the inner side of mem-
brane was bu¡ered with 8 mM EGTA to 0.01 WM, calculated using
‘Maxc Software’ (from Chris Patton, Hopkins Marine Station, Stan-
ford University).
Results are expressed as meansO standard deviation where appro-
priate. Each experiment was repeated several times. Student’s t-test
was used for statistical comparison among means, and di¡erences
with P6 0.05 were considered signi¢cant.
2.5. Computer analysis
Nucleic acid and protein sequences were compared with sequences
in the GenBank databases using program BLAST. The ‘Search the
Conserved Domain Database using RPS-BLAST’ (http://www.ncbi.
nlm.nih.gov/Structure/cdd/wrpsb.cgi) program has been used for
search of conservative domains. The sequences of the open reading
frames of the KCNRG and KCNRG-like genes were aligned, using the
ClustalW program (www2.ebi.ac.uk/ClustalW/).
3. Results and discussion
3.1. Molecular cloning of a novel putative tumor suppressor
gene KCNRG
To identify the candidate for tumor suppressor genes for
BCLL and prostate cancer locus at 13q14.3, an integrated
genomic contig [8] and corresponding transcript map [9]
were constructed. The new gene KCNRG was found via
BLASTN search of the EST database of GenBank seeded
with a genomic sequence (AF440619). As a result we retrieved
two expressed human sequences with the accession numbers
BI770863 and BG537776. Corresponding cloned cDNAs IM-
AGE: 5207702 and IMAGE: 4690662 were completely se-
quenced (mRNAs AY129654 and AY129653) and found to
contain two full-length coding sequences corresponding to
di¡erent mRNA isoforms that belongs to the same gene.
Sequence alignment of the genomic locus AF440619, which
consists of 350 000 bases with the KCNRG mRNAs
AY129654 and AY129653 revealed genomic structure of
5460 bp KCNRG. mRNA AY129654 consists of two exons
(612 nt and 709 nt in size) divided in genome by single intron
4139 nt in size, mRNA AY129653 consists of three exons
(612, 95 and 709 nt in size) divided by two introns (2750
and 1292 nt in size). All of the intron^exon junctions con-
formed to the consensus splice sites, GT and AG, for donor
and acceptor sequences, respectively (data not shown). The
mRNA isoforms AY129654 and AY129653 result from alter-
native splicing events (Fig. 1).
3.2. Analysis of amino acidic sequence encoded by gene
KCNRG
As the newly found gene encodes a protein with strong
amino acidic sequence similarity to cytoplasmic tetrameriza-
tion domain (T1) of voltage-gated Kþ channels, we assigned
to this gene a name KCNRG (Kþ channel regulator) and
Fig. 1. A: Position of genes in the BCLL critical region in 13q14.3; B: genomic structure of KCNRG.
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registered the mRNA isoforms as AY129654 (1345 nt encod-
ing 272 aa) and AY129653 (1465 nt encoding 229 aa). Hydro-
philicity analysis of the amino acid sequences encoded by
mRNAs AY129654 and AY129653 showed that both of
them are soluble proteins that di¡er only in their C-terminal
amino acidic sequences. The N-termini are identical in their
amino acidic sequences and both isoforms show strong ho-
mology (e-value 8e^14) to T1 domain (pfam 02214) of vol-
tage-gated Kþ channels (Fig. 2) and to BTB/POZ domain
with considerably lower e-value equal 3.90e^06. T1 domain
of voltage-gated Kþ channels encodes molecular determinants
for subfamily-speci¢c assembly of K-subunits into functional
tetrameric channels. A presence of T1 domain structure in the
KCNRG suggested that protein might interfere with normal
assembly of the K+ channel proteins and their tetramerization
thus causing the suppression of the K+ channels.
3.3. Tissue distribution of KCNRG mRNA isoforms
RT-PCR analysis for human multiple mRNA showed that
KCNRG mRNA was expressed in normal and some tumor
tissues (Fig. 3). With 35 cycles of PCR electrophoretically
visible bands corresponding to both alternatively spliced
mRNA isoforms of the gene KCNRG were detected in normal
lung, lymphocytes, prostate and tumor cell lines human colon
carcinoma (Lim 1215), human epidermal carcinoma (A431),
human breast cancer (T47D) and human osteogenic sarcoma
(SAOS-2). KCNRG was expressed highly in normal lung.
With 39 cycles of PCR DNA bands of the same weight
were visible also in the normal kidney, stomach, brain, but
not in the tumor cell lines of metastatic prostate carcinoma
(LNCaP), ovarian epithelial carcinoma (SKOV-3), osteosarco-
ma (T113).
3.4. Electrophysiological study protein KCNRG
To test the hypothesis that the KCNRG protein is able to
interfere with the normal function of the Kþ channels (see
above), we cloned KCNRG sequence in to pEGFP-N1 vector
and used this construction to express KCNRG-GFP in
LNCaP human prostate derived cell culture. In the experi-
ments with the whole-cell patch-clamp technique potassium
current was measured in 38 transfected and in 32 non-trans-
fected LNCaP cells. The average Kþ current density in trans-
fected cells (78.9 O 26.2 pA/pF, n=38) was two times lower
than in the control cells (164.8 O 38.7 pA/pF, n=32) as shown
in Fig. 4A. It is di⁄cult to compare Kþ currents directly in
the individual transfected and non-transfected cells because of
the very broad diversity of individual Kþ currents. To over-
come this problem we focused on symmetrical recently divided
cell pairs. Indeed such pairs had rather close values of Kþ
current (17O 8% di¡erence, n=10) and practically the same
membrane capacitance, although Kþ current alone varied
strongly between di¡erent pairs (between 80 and 196 pA/
pF). We investigated four cases where one cell from pair
was transfected while the second one was not transfected
(Fig. 4B). In all these cases, Kþ currents were obviously lower
in transfected cells than in non-transfected ones. Fig. 4C,D
shows an example of the family of Kþ currents (C) obtained
Fig. 2. Alignment of KCNRG to selected proteins containing of T1 domain. Black boxes indicate residues that are conserved among 247 pri-
mary sequences from GenBank.
Fig. 3. Tissue distribution of isoforms mRNA gene KCNRG. A: RT-
PCR analysis for human multiple mRNA with 35 cycles; B: RT-
PCR analysis for human multiple mRNA with 39 cycles; C: Total
RNA from cultures of tumor cells were used for RT-PCR of
KCNRG with 35 cycles. As the positive control of these RT-PCR
reactions, GAPDH was ampli¢ed (data not shown).
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in transfected and control non-transfected LNCaP cells
evoked by 400 ms depolarizing pulses from a holding poten-
tial of 380 mV to various membrane potentials (3120 to
+100 mV) and the corresponding current^voltage relationship
(D).
In control experiments with LNCaP cells transfected with
EGFP alone no di¡erence was detected in Kþ currents be-
tween transfected (N=11) and non-transfected (N=37) cells
(data not shown).
3.5. Summary
In this report, we describe the cloning of KCNRG, a novel
Kþ channel regulator encoding gene, which was identi¢ed by
human genome sequence database search for a new genes
located in 13q14.3. KCNRG gene contains three exons, includ-
ing one that can be spliced producing two alternative mRNA
isoforms. This gene is ubiquitously expressed since it was
present in all normal and some tumor tissues analyzed.
KCNRG encodes a soluble protein. Analysis of protein se-
quence databases revealed a signi¢cant homology between the
KCNRG N-termini amino acid sequence and the domain T1
of voltage-gated Kþ channels. Electrophysiological study on
LNCaP cell reveals that KCNRG protein expression inhibits
Kþ £uxes.
As voltage-gated Kþ channels are upregulated in immature
neoplastic BCLL cells and as their selective blockers suppress
lymphocyte and LNCaP human prostate cancer cell lines pro-
liferation, we suggest that KCNRG is a candidate for a BCLL
and prostate cancer tumor suppressor gene in human 13q14.3.
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